NASDAQ:RAPP Rapport Therapeutics Q1 2025 Earnings Results & Report $26.15 +0.30 (+1.16%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$25.75 -0.40 (-1.53%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Rapport Therapeutics beat analyst earnings expectations in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.68 versus the -$0.77 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call7:00 AM ET Rapport Therapeutics EPS ResultsActual EPS-$0.68Consensus EPS -$0.77Beat/MissBeat by +$0.09One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersRapport Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rapport Therapeutics Q1 2025 Earnings FAQ Did Rapport Therapeutics beat earnings estimates for Q1 2025? Rapport Therapeutics (NASDAQ:RAPP) reported earnings of -$0.68 per share for Q1 2025, beating the consensus estimate of -$0.77. The report was announced on Thursday, May 8, 2025. Rapport Therapeutics Earnings HeadlinesHC Wainwright Analysts Increase Earnings Estimates for RAPPNovember 9, 2026 | americanbankingnews.comUBS Adjusts Rapport Therapeutics Price Target to $64 From $71, Maintains Buy RatingNovember 5, 2026 | marketscreener.comMTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 14 at 1:00 AM | Base Camp Trading (Ad)Rapport Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMRapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business UpdateNovember 4, 2026 | finance.yahoo.comRapport Therapeutics (NASDAQ:RAPP) Sees Large Volume Increase After Insider Buying ActivityNovember 4, 2026 | americanbankingnews.comSee More Rapport Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rapport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapport Therapeutics and other key companies, straight to your email. Email Address About Rapport TherapeuticsRapport Therapeutics (NASDAQ:RAPP) is a Boston-based biotechnology company developing medicines for neurological and psychiatric disorders. Founded in 2022, the company focuses on small molecules designed to act on mechanisms that regulate the movement and function of proteins in the brain. Its research platform is intended to identify targets involved in neuronal signaling, including interactions that influence ion channels. Rapport’s pipeline includes RAP-219, an investigational medicine that modulates AMPA receptors and is being developed for focal epilepsy. The company’s work is centered on discovering and developing treatments for conditions with limited or inadequate therapeutic options. Its development programs are investigational, and no product description here should be taken to imply regulatory approval.View Rapport Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
